Trexquant Investment LP Sells 51,759 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Trexquant Investment LP decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 227,598 shares of the company’s stock after selling 51,759 shares during the quarter. Trexquant Investment LP’s holdings in Cellebrite DI were worth $5,014,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Quarry LP bought a new position in Cellebrite DI in the 3rd quarter valued at about $27,000. R Squared Ltd bought a new position in shares of Cellebrite DI during the fourth quarter worth approximately $100,000. Polen Capital Management LLC acquired a new stake in Cellebrite DI during the 4th quarter worth approximately $222,000. Victory Capital Management Inc. bought a new stake in Cellebrite DI in the 4th quarter valued at $234,000. Finally, HighTower Advisors LLC acquired a new position in Cellebrite DI in the 4th quarter valued at $274,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Down 5.6 %

CLBT stock opened at $17.71 on Friday. The company’s 50-day moving average price is $20.41 and its two-hundred day moving average price is $19.95. The firm has a market cap of $4.24 billion, a P/E ratio of -12.74, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Equities analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday. Finally, Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.